Clinical Trial

SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer

Study acronym: CRIT
Completed Phase 2
View on ClinicalTrials.gov →
Summary
To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-05
notable Primary completion moved earlier: 2027-04-01 -> 2026-04-22 2026-08-05
minor Completion moved earlier: 2027-04-01 -> 2026-04-22 2026-08-05
Trial Details
NCT Number NCT06908031
Lead Sponsor Sixth Affiliated Hospital, Sun Yat-sen University
Conditions Rectal Adenocarcinoma, High-Risk Cancer, MSS
Enrollment 49 participants
Start Date 2025-04-02
Primary Completion 2026-04-22 (estimated)
Study Completion 2026-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-04